Newmont Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Newmont Corporation trades at $119.02 (market cap $123.56B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Newmont Corporation is far larger — about 69.4× Recursion Pharmaceuticals Inc's market cap, and Newmont Corporation pays a 0.89% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NEM | RXRX | |
|---|---|---|
Market Cap | $123.56B | $1.78B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $6.79 |
52-Week Low | $67.38 | $2.84 |
Enterprise Value | $120.14B | $1.30B |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →